Cardinal Health (CAH) EBITDA (2009 - 2026)

Cardinal Health (CAH) has 18 years of EBITDA data on file, last reported at $509.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 30.27% year-over-year to $509.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (up 2.85% YoY), and the FY2025 full-year result was $2.3 billion, up 83.02% from the prior year.
• EBITDA declined to $509.0 million in Q1 2026, from $707.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $730.0 million in Q1 2025 to a low of -$97.0 million in Q1 2022.
• A 5-year average of $358.9 million and a median of $428.0 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 126.02% in 2023 and surged 1875.0% in 2024, its largest moves.
• Tracing CAH's EBITDA over 5 years: stood at -$86.0 million in 2022, then jumped by 687.21% to $505.0 million in 2023, then increased by 8.71% to $549.0 million in 2024, then climbed by 28.78% to $707.0 million in 2025, then retreated by 28.01% to $509.0 million in 2026.
• Business Quant data shows CAH's EBITDA at $509.0 million in Q1 2026, $707.0 million in Q4 2025, and $668.0 million in Q3 2025.